Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29216927 | 0.69 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL6476265 | 0.66 | SMN1; SMN2 (0.37) | SMN1; SMN2IKBKB | |
| Hydrochloric Acid SCHEMBL7813040 | 0.64 | SMN1; SMN2 (0.60) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL28068800 | 0.64 | POLB (0.39) | SMN1; SMN2KMT2ALDHALDHBL3MBTL1 | |
| SCHEMBL3648497 | 0.63 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2A | |
| SCHEMBL6484070 | 0.63 | KDM4E (0.38) | SMN1; SMN2IKBKBL3MBTL1 | |
| SCHEMBL6601847 | 0.62 | NOS2 (0.39) | KMT2AUSP2IKBKBLDHALDHB | |
| SCHEMBL6641959 | 0.61 | IKBKB (0.36) | SMN1; SMN2IKBKB | |
| SCHEMBL28280172 | 0.61 | PTGES (0.43) | SMN1; SMN2KMT2A | |
| SCHEMBL2461639 | 0.60 | ALDH1A1 (0.39) | SMN1; SMN2KMT2AUSP2IKBKBLDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962911-B2 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2005-11-08 | — | — | US | disclosed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | SMN1; SMN2 2323/4885KMT2A 4373/4885USP2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.